Seven Corners Capital 

We've been following the progress of SEAC since investing in the company far too modestly in size :( earlier this year. At the time of purchase, SEAC fit our target profile of a small company undergoing rapid change due to exogenous events, creating a compelling risk-reward opportunity when the company's stock became (we believe temporarily) severely depressed due to investor uncertainty over operational challenges related to the transition of the company's business model fr

Further to our previous coverage of MACK, this is a quick update blog to note that the trials for Onivyde by Ipsen for both pancreatic cancer and SSLC have advanced to Phase III. Below are Ipsen's pipeline flow charts from both the end of July 2019 (included in our blog post of that date, which can be found here) and currently (see source here): Thus MACK shareholders are one step closer to receiving the CVR payouts for each of these trials (assuming they result in FDA approv

Continuing our coverage of CCUR Holdings (see prior blog posts, as well as our writeup in our Research section), the company today announced in a press release (see full PR here) that it has "initiated further review of capital allocation alternatives to maximize stockholder value, including a potential limited return of capital to stockholders through a special distribution" (emphasis added). It's worth noting that, as of the most recent quarter end, CCUR had $15.8 million i

We did a quick and dirty analysis of the last year's worth of Rite Aid's (RAD) press releases (see links to RAD's PRs here), in order to determine how much RAD's senior management (i.e., those putting out the PRs) prioritizes improving the customer experience, versus (for example) addressing the interests of investors, employees or charities. What we found was quite interesting. Out of the approximately 60 PRs issued by RAD over the past year, only 11 were PRs announcing how

In this post we quickly examine the most recent earnings report from CCUR Holdings (ticker CCUR), issued on November 1st (yes, we are very late, apologies!). For reference, please see (A) the company's Q1 FY 2020 earnings press release here and Form 10-Q filing here for a much more in-depth review and (B) a chart showing the recent performance of the company's shares immediately below: CCUR reported positive net income of $3.4 million in the quarter, which might not sound lik